Thyroid Eye Disease – Unmet Need – Unmet Need – Thyroid Eye Disease US/EU

Thyroid eye disease (TED) is a rare, vision-threatening autoimmune disorder that typically begins with an active inflammatory phase before progressing to a chronic stage. Amgen’s Tepezza is the only approved therapy for the indication in the United States, offering meaningful clinical benefits while underscoring the continued need for accessible and safe long-term treatment options. In Europe, where Tepezza is not yet available, physicians rely on low-cost IV glucocorticoids and biologics such as rituximab or tocilizumab for active, moderate to severe TED patients. Across both regions, growing interest in next-generation IGF-1R and FcRn-targeting agents reflects the need for safer, more consistent, and durable responses in this heterogeneous disease. As pipeline activity accelerates and treatment practices evolve, understanding treatment opportunities and regional differences is essential to closely monitor evolving physician needs in TED.

QUESTIONS ANSWERED

• How do oculoplastic surgeons and ophthalmologists perceive the current therapies as performing on key treatment drivers and goals for active, moderate to severe TED?
• What clinical and nonclinical attributes most influence prescribing decisions in active, moderate to severe TED in the United States and Europe?
• What are the prevailing areas of unmet need and opportunity in active, moderate to severe TED?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European oculoplastic surgeons and ophthalmologists for a novel TED therapy?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 45 oculoplastic surgeons and 46 ophthalmologists in February 2026 (60 in the United States and 31 in Europe)

Key drugs covered: Tepezza, rituximab, tocilizumab, mycophenolate, methylprednisolone

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.